Stuart Ince

550 total citations
21 papers, 291 citations indexed

About

Stuart Ince is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Stuart Ince has authored 21 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Stuart Ince's work include Fibroblast Growth Factor Research (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Cancer-related Molecular Pathways (5 papers). Stuart Ince is often cited by papers focused on Fibroblast Growth Factor Research (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Cancer-related Molecular Pathways (5 papers). Stuart Ince collaborates with scholars based in Germany, United States and Spain. Stuart Ince's co-authors include Dominik Mumberg, Karl Ziegelbauer, Franz von Nussbaum, Peter Ellinghaus, Oliver Politz, Arne Scholz, Ulf Bömer, Mélanie Héroult, Ray Valencia and Ulf Boemer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Stuart Ince

21 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart Ince Germany	9	208	102	64	53	30	21	291
Meizhong Xu United States	5	134 0.6×	74 0.7×	75 1.2×	61 1.2×	21 0.7×	5	295
Rachael Brake United States	10	166 0.8×	82 0.8×	87 1.4×	25 0.5×	11 0.4×	26	269
Chunhong He United States	6	138 0.7×	86 0.8×	74 1.2×	18 0.3×	21 0.7×	21	278
Oliver Schadt Germany	9	172 0.8×	105 1.0×	76 1.2×	33 0.6×	16 0.5×	17	319
Sachie Otsuki Japan	5	143 0.7×	76 0.7×	28 0.4×	50 0.9×	56 1.9×	5	233
Hiromi Kazuno Japan	10	193 0.9×	186 1.8×	58 0.9×	20 0.4×	21 0.7×	11	342
Mally Romero United States	4	364 1.8×	143 1.4×	53 0.8×	36 0.7×	16 0.5×	5	475
Tracy Lou United States	3	209 1.0×	90 0.9×	57 0.9×	32 0.6×	15 0.5×	3	334
Shana Y. Trostel United States	8	260 1.3×	166 1.6×	71 1.1×	24 0.5×	14 0.5×	11	396
Jared Bearss United States	6	164 0.8×	60 0.6×	66 1.0×	34 0.6×	14 0.5×	11	286

Countries citing papers authored by Stuart Ince

Since Specialization

Citations

This map shows the geographic impact of Stuart Ince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Ince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Ince more than expected).

Fields of papers citing papers by Stuart Ince

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Ince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Ince. The network helps show where Stuart Ince may publish in the future.

Co-authorship network of co-authors of Stuart Ince

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Ince. A scholar is included among the top collaborators of Stuart Ince based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Ince. Stuart Ince is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lücking, Ulrich, Dirk Kosemund, Niels Böhnke, et al.. (2021). Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. Journal of Medicinal Chemistry. 64(15). 11651–11674. 53 indexed citations

Grünewald, Sylvia, Oliver Politz, Sebastian Bender, et al.. (2019). Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. International Journal of Cancer. 145(5). 1346–1357. 72 indexed citations

Diamond, Jennifer R., Víctor Moreno, Emerson A. Lim, et al.. (2018). Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity.. Journal of Clinical Oncology. 36(15_suppl). 2507–2507. 10 indexed citations

Byrne, Michael, Mark G. Frattini, Oliver G. Ottmann, et al.. (2018). Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia. Blood. 132(Supplement 1). 4055–4055. 16 indexed citations

Tahara, Makoto, Shunji Takahashi, Matthias Ocker, et al.. (2018). Abstract A099: Safety, tolerability, pharmacokinetics, and efficacy of pan-fibroblast growth factor receptor inhibitor rogaratinib in Japanese patients with refractory, locally advanced metastatic solid tumors selected with a novel, mRNA-based patient selection strategy. Molecular Cancer Therapeutics. 17(1_Supplement). A099–A099. 1 indexed citations

Joerger, Markus, Martin Schüler, Philippe A. Cassier, et al.. (2017). Patient selection using novel RNA-based approaches: Early experience from a phase I study with the pan-FGFR inhibitor BAY 1163877 in patients with urothelial bladder cancer.. Journal of Clinical Oncology. 35(6_suppl). 386–386. 4 indexed citations

Scholz, Arne, Dirk Kosemund, Rolf Bohlmann, et al.. (2017). Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops. Cancer Research. 77(13_Supplement). 984–984. 26 indexed citations

Politz, Oliver, Franziska Siegel, Lars Bärfacker, et al.. (2016). BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models. International Journal of Cancer. 140(2). 449–459. 51 indexed citations

Politz, Oliver, Stuart Ince, Andrea Haegebarth, et al.. (2016). Abstract 379: Allosteric AKT1/2-inhibitor BAY 1125976 as potent inhibitor in luminal breast cancer resistant to antihormone therapy. Cancer Research. 76(14_Supplement). 379–379. 2 indexed citations

10.

Scholz, Arne, Thomas Oellerich, Akhtar Hussain, et al.. (2016). Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). Cancer Research. 76(14_Supplement). 3022–3022. 17 indexed citations

11.

Haendler, Bernard, Kathy A. Gelato, Laura Schöckel, et al.. (2016). Abstract 4703: The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models. Cancer Research. 76(14_Supplement). 4703–4703. 3 indexed citations

12.

Scholz, Arne, Gerhard Siemeister, Philip Lienau, et al.. (2015). Abstract DDT02-02: BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. Cancer Research. 75(15_Supplement). DDT02–2. 8 indexed citations

13.

Héroult, Mélanie, Matthias Ocker, Charlotte Kopitz, et al.. (2015). Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin. Cancer Research. 75(15_Supplement). 772–772. 5 indexed citations

14.

Lejeune, Pascale, Tatsuo Sugawara, Kathy A. Gelato, et al.. (2015). Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research. 75(15_Supplement). 3524–3524. 5 indexed citations

15.

Héroult, Mélanie, Peter Ellinghaus, Dirk Brohm, et al.. (2014). Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 74(19_Supplement). 1739–1739. 9 indexed citations

16.

Politz, Oliver, Arne Scholz, Andrea Haegebarth, et al.. (2014). Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers. Cancer Research. 74(19_Supplement). 3685–3685. 1 indexed citations

17.

Héroult, Mélanie, Peter Ellinghaus, Stuart Ince, & Matthias Ocker. (2014). Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment. Current Signal Transduction Therapy. 9(1). 15–25. 3 indexed citations

18.

Scholz, Arne, Ulrich Lücking, Gerhard Siemeister, et al.. (2014). Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity. Cancer Research. 74(19_Supplement). 4538–4538. 1 indexed citations

19.

Politz, Oliver, Stuart Ince, William J. Scott, et al.. (2013). Abstract 2050: BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway.. Cancer Research. 73(8_Supplement). 2050–2050. 2 indexed citations

20.

Thierauch, Karl‐Heinz, Martin Haberey, Holger Hess‐Stumpp, et al.. (2007). ZK 261991. a novel VEGFR inhibitor for tumor therapy. Cancer Research. 67. 2135–2135. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact